Alkem Labs Q1 FY27 Call Transcript Released: Revenue Up 11% to ₹3,740 Cr
Alkem Laboratories reported Q1 FY27 revenue of ₹3,740 Cr, up 11% YoY. India sales grew 10.3% to ₹2,497 Cr, and international sales rose 16% to ₹1,222 Cr. EBITDA margin stood at 20.5%. Net profit declined 21.7% due to taxation. The company outperformed the Indian pharmaceutical market.
The announcement provides detailed financial results and operational updates for the quarter, including revenue growth, segment performance, and regulatory updates. This information is material for investors and analysts to assess the company's performance and outlook, thus having a medium impact.
The announcement is a transcript release of a conference call discussing Q1 FY27 results. While revenue and international sales showed positive growth, net profit declined, and there were discussions about challenges in the Trade Generics segment and increased costs. The overall sentiment is neutral as it presents a balanced view of performance and challenges.
Alkem Laboratories Limited has released the transcript of its Q1 FY27 earnings conference call, which was hosted on August 14, 2026. The company reported revenue from operations of ₹3,740 crore, an 11% year-on-year growth. India sales stood at ₹2,497 crore, with a 10.3% growth, while international sales reached ₹1,222 crore, marking a 16% increase. The EBITDA margin was reported at 20.5%, with a 3.7% year-on-year growth. R&D expenses were 4% of total revenue.
Profit before tax saw a marginal 1.8% growth, while net profit experienced a degrowth of 21.7%, attributed primarily to taxation reasons. The company outperformed the Indian pharmaceutical market (IPM) in terms of growth, with a 13.2% year-on-year increase compared to the IPM's 12.2%. The acute segment grew by 12.3% versus the IPM's 10.1%, and the chronic segment grew by 17.9% versus the IPM's 15.4%.
During the quarter, Alkem received 5 ANDA approvals for the U.S. market, one of which was tentative. The Daman facility received an OAI status, and the company is undertaking corrective actions, with product supplies to the U.S. market continuing without interruption. The company's Trade Generics business experienced flattish growth, which dragged down the overall India sales growth. Branded generics, however, grew by 12%.
Discussions also covered increased employee costs due to annual increments and the addition of new MRs, as well as expenses related to the Enzene CDMO business and higher conversion rates for the dollar. The MedTech business, including the acquisition of Occlutech, is expected to break even within the next 12 months. The company is also targeting USD 25-30 million in annualized revenue for the U.S. CDMO business to achieve breakeven, with a focus on monoclonal antibodies.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.